<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg"/></p>
<p>兩家公司將共同監督抗體候選藥物的早期開發。來源：SmartPhotoLab / Shutterstock.com。</p>
<p>SciNeuro Pharmaceuticals 宣佈與諾華製藥達成全球許可和合作協議，以開發 SciNeuro 新發現的去新型澱粉樣β抗體項目，旨在治療阿爾茨海默病。</p>
<p>該協議將利用 SciNeuro 的專有血腦屏障運輸技術，旨在與當前正在開發或市場上的澱粉樣β藥物形成潛在差異化。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM：禮來公司的 Remternetug</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM：SanBio 有限公司的 SB-623</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>兩家公司將共同監督抗體候選藥物的早期開發。在初始階段之後，諾華將承擔全球範圍內所有後續產品開發和商業化的責任。</p>
<p>根據協議條款，SciNeuro 將獲得 1.65 億美元的預付款。該公司還可能獲得研究資金，以及高達 15 億美元的潛在開發、監管和商業里程碑。還將提供分級版税。</p>
<p>交易的完成預計在 2026 年上半年，需遵循 1976 年哈特 - 斯科特 - 羅迪諾反壟斷改進法案的等待期結束或豁免，並滿足慣例的成交條件。</p>
<p>SciNeuro 創始人兼首席執行官 Min Li 表示：“抗澱粉樣蛋白項目是 SciNeuro 針對神經退行性疾病的關鍵戰略研發優先事項之一。我們很高興能與諾華合作繼續開發這一項目，考慮到其在神經退行性疾病下一代療法方面的卓越能力和承諾。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<p>“這次合作實現了最佳的協同效應，將我們在疾病生物學和早期開發方面的專業知識與諾華在臨牀開發和商業化方面的全球領導地位相結合。”</p>
<p>諾華生物醫學研究神經科學全球負責人 Robert Baloh 表示：“迫切需要新的和差異化的治療方法，以幫助緩解阿爾茨海默病等毀滅性神經疾病的痛苦。</p>
<p>“我們很高興能與 SciNeuro 合作，該組織擁有專有技術，旨在安全有效地靶向澱粉樣β，並與我們對這一疾病領域的緊迫感和承諾相一致。”</p>
<p>2025 年 10 月，諾華與美國 Avidity Biosciences 簽署了一項協議，以 120 億美元的現金收購其所有未償還股份，按完全稀釋基礎計算。</p>

諾華制藥

<p>SciNeuro Pharmaceuticals 與諾華製藥達成了一項全球許可協議，旨在開發用於阿爾茨海默病的澱粉樣β抗體。此次合作將重點關注早期開發，諾華將在後期階段和商業化方面接手。SciNeuro 將獲得 1.65 億美元的預付款、潛在的研究資金以及高達 15 億美元的里程碑付款。該交易預計將在 2026 年上半年完成，待監管機構批准。兩家公司旨在利用各自的專業知識，滿足對新阿爾茨海默病療法的迫切需求</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-2-13-01-2025-shutterstock_1933081766-430x241.jpg"/></p>
<p>Both companies will jointly oversee early-stage development of the antibody candidates. Credit: SmartPhotoLab / Shutterstock.com.</p>
<div class="lb-trans"><p>兩家公司將共同監督抗體候選藥物的早期開發。來源：SmartPhotoLab / Shutterstock.com。</p>
</div><p>SciNeuro Pharmaceuticals has announced a global licensing and collaboration agreement with Novartis to develop SciNeuro’s newly identified de novo amyloid beta antibody programme aimed at treating Alzheimer’s disease.</p>
<div class="lb-trans"><p>SciNeuro Pharmaceuticals 宣佈與諾華製藥達成全球許可和合作協議，以開發 SciNeuro 新發現的去新型澱粉樣β抗體項目，旨在治療阿爾茨海默病。</p>
</div><p>The agreement will leverage SciNeuro’s proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market.</p>
<div class="lb-trans"><p>該協議將利用 SciNeuro 的專有血腦屏障運輸技術，旨在與當前正在開發或市場上的澱粉樣β藥物形成潛在差異化。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Eli Lilly and Co's Remternetug</h4>
<div class="lb-trans"><h4>NPVM：禮來公司的 Remternetug</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: SanBio Co Ltd's SB-623</h4>
<div class="lb-trans"><h4>NPVM：SanBio 有限公司的 SB-623</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Both companies will jointly oversee early-stage development of the antibody candidates. Following the initial stages, Novartis will assume responsibility for all further product development and commercialisation worldwide.</p>
<div class="lb-trans"><p>兩家公司將共同監督抗體候選藥物的早期開發。在初始階段之後，諾華將承擔全球範圍內所有後續產品開發和商業化的責任。</p>
</div><p>Under the agreed terms, SciNeuro will receive an upfront payment of $165m. The company may also receive research funding, along with up to $1.5bn in potential development, regulatory and commercial milestones. Tiered royalties will also be available.</p>
<div class="lb-trans"><p>根據協議條款，SciNeuro 將獲得 1.65 億美元的預付款。該公司還可能獲得研究資金，以及高達 15 億美元的潛在開發、監管和商業里程碑。還將提供分級版税。</p>
</div><p>Completion of the transaction is anticipated in the first half of 2026, subject to the end or waiver of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period and fulfilment of customary closing conditions.</p>
<div class="lb-trans"><p>交易的完成預計在 2026 年上半年，需遵循 1976 年哈特 - 斯科特 - 羅迪諾反壟斷改進法案的等待期結束或豁免，並滿足慣例的成交條件。</p>
</div><p>SciNeuro founder and CEO Min Li said: “The anti-amyloid programme represents one of SciNeuro’s key strategic R&amp;D priorities to target neurodegenerative disease. We are thrilled to collaborate with Novartis to continue its development, given its preeminent capabilities and commitment to next-generation therapies for neurodegenerative diseases.</p>
<div class="lb-trans"><p>SciNeuro 創始人兼首席執行官 Min Li 表示：“抗澱粉樣蛋白項目是 SciNeuro 針對神經退行性疾病的關鍵戰略研發優先事項之一。我們很高興能與諾華合作繼續開發這一項目，考慮到其在神經退行性疾病下一代療法方面的卓越能力和承諾。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>“This collaboration delivers an optimal synergy, combining our expertise in disease biology and early development with Novartis’ global leadership in clinical development and commercialisation.”</p>
<div class="lb-trans"><p>“這次合作實現了最佳的協同效應，將我們在疾病生物學和早期開發方面的專業知識與諾華在臨牀開發和商業化方面的全球領導地位相結合。”</p>
</div><p>Novartis biomedical research neuroscience global head Robert Baloh said: “There is a pressing need for new and differentiated therapeutics to help alleviate suffering in devastating neurological diseases such as Alzheimer’s disease.</p>
<div class="lb-trans"><p>諾華生物醫學研究神經科學全球負責人 Robert Baloh 表示：“迫切需要新的和差異化的治療方法，以幫助緩解阿爾茨海默病等毀滅性神經疾病的痛苦。</p>
</div><p>“We are happy to be collaborating with SciNeuro, an organisation which has proprietary technology aiming to safely and effectively target amyloid beta and which shares our sense of urgency and commitment to this disease area.”</p>
<div class="lb-trans"><p>“我們很高興能與 SciNeuro 合作，該組織擁有專有技術，旨在安全有效地靶向澱粉樣β，並與我們對這一疾病領域的緊迫感和承諾相一致。”</p>
</div><p>In October 2025, Novartis signed an agreement to acquire all outstanding shares of US-based Avidity Biosciences for $12bn in cash on a fully diluted basis.</p>
<div class="lb-trans"><p>2025 年 10 月，諾華與美國 Avidity Biosciences 簽署了一項協議，以 120 億美元的現金收購其所有未償還股份，按完全稀釋基礎計算。</p>
</div>

SciNeuro 與諾華製藥簽署全球許可協議，開發阿爾茨海默症抗體